How are energy investors positioned?
On Friday, RBC Capital Markets reiterated an Outperform rating on Tenet Healthcare Corporation (NYSE:THC) with a price target of $136.00. The firm's analyst Ben Hendrix highlighted Tenet Healthcare, currently valued at $11.54 billion in market cap, as the top hospital pick for the year. With a compelling P/E ratio of 3.67x and strong EBITDA of $4.036 billion, the company shows potential for near-term upside as first-quarter earnings approach on April 16.
Hendrix pointed out that despite the ongoing policy uncertainty facing providers, especially hospitals, Tenet Healthcare is comparatively less exposed to potential Medicaid cuts. Based on the analysis from Monday, Hendrix suggested that a reduction in state provider tax hold-harmless limits would have less than a 2% impact on Tenet's 2026 EBITDA. According to InvestingPro, the company maintains a "GREAT" financial health score of 3.49, with a robust gross profit margin of 39.72%, supporting the added security provided by its expanding ambulatory surgery platform.
The analyst believes that Tenet's enterprise multiple, which is nearly 2x lower than that of sector leader HCA (NYSE:HCA), does not reflect the company's true value. Hendrix cited several reasons for this belief, including Tenet's comparable consolidated margins, improvements in the balance sheet resulting from accretive asset sales, and a robust growth profile driven by ambulatory surgery center (ASC) development. Discover more valuable insights about THC's valuation and growth potential with InvestingPro, which offers 8 additional exclusive ProTips and comprehensive financial analysis.
Tenet Healthcare's financial position has been strengthened by strategic asset sales, which have enhanced the balance sheet and contributed to the company's growth. The analyst's positive outlook is also supported by Tenet's growth through its development of ambulatory surgery centers, which are expected to continue contributing to the company's performance.
In conclusion, RBC Capital Markets' stance on Tenet Healthcare remains positive, with expectations of continued growth and resilience in the face of industry challenges. The Outperform rating and $136.00 price target reflect the firm's confidence in Tenet's strategic positioning and financial prospects.
In other recent news, Tenet Healthcare Corporation has seen several developments that may interest investors. Fitch Ratings upgraded Tenet Healthcare's Issuer Default Rating from 'B+' to 'BB-', citing the company's improved competitive position and substantial debt reduction. This upgrade reflects Tenet's strong EBITDA growth, particularly in its Ambulatory Care segment, and a significant reduction of debt by $2.1 billion. Analysts from Guggenheim initiated coverage with a Buy rating and a $165 price target, highlighting Tenet's focus on expanding its Ambulatory business and revamping hospital operations. Cantor Fitzgerald maintained an Overweight rating with a $177 price target, noting stable nursing trends but potential challenges in the anesthesia physician segment. Jefferies also maintained an Outperform rating with a $185 price target, indicating confidence in Tenet's valuation despite potential healthcare spending cuts. Morgan Stanley (NYSE:MS) set an Overweight rating with a $165 target, emphasizing Tenet's strategic positioning to capitalize on the shift towards outpatient services. These developments underscore the varied analyst perspectives on Tenet Healthcare's financial health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.